On Mar. 14, 2025, Sanofi announced that it plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining other drugmakers in expanding their U.S. presence in response to President Donald Trump’s trade policies.

The French drugmaker, one of the world’s largest vaccine makers and a leader in anti-inflammatory drugs, said on Wednesday it plans to expand its U.S. manufacturing capacity through direct investments in Sanofi sites, and partnerships with other domestic manufacturers.

The U.S. made up about 47% of Sanofi’s total revenue in the first quarter of 2025. Analysts and industry executives have said any new manufacturing facility could take at least five years to begin production.